Juno Therapeutics Gmbh

Claire L Sutherland

Christopher Glen Ramsborg

Mark J Gilbert

He Li

Brian Christin

Clinton Weber

Rachel K Yost

Tina Albertson

Ryan P Larson

Jacob Randolph Garcia

Nathan K Yee

Kedar Himanshu Dave

Jeff D Smith

Pascal Beauchesne

Valerie Odegard

Kathryn Lindsay Pollock

Tom Kowski

Ronald James Hause, Jr

Mary Mallaney

Andrew W Walker

Nikolaus Sebastian Trede

Todd Devries

Michael Gerard Covington

Richard James Getto, Jr

James Boyd Whitmore

Travis Beckett

Samuel Charles Blackman

Nathaniel Chartrand

Nathaniel Lambert

Mel Davis-pickett

Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Determining toxicity risk in CAR T-cell therapy

Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.

Phenotypic markers for cell therapy and related methods

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

Articles of manufacture and methods for treatment using adoptive cell therapy

Growing community of inventors

Seattle, WA, United States of America

Claire L Sutherland